Skip to content
Open access · CC-BY via OpenAlex

Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors

Carolina Becker Livi, Rulon L. Hardman, Barbara A. Christy, Sherry G. Dodds, Diane Jones, Charnae E. Williams, Randy Strong, Alex F. Bokov, Martin A. Javors, Yuji Ikeno, Gene B. Hubbard, Paul Hasty, Zelton Dave Sharp

Aging · 2013 · ▲ 86 citations

Abstract

Chronic treatment of mice with an enterically released formulation of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of thesein vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1+/- mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1+/- mice, suggesting that the beneficial response to DR is dependent on pRb1. Since long-term eRapa treatment may at least partially mimic chronic DR in lifespan extension, we predicted that it would have a minimal effect in Rb1+/- mice. Beginning at 9 weeks of age until death, we fed Rb1+/- mice a diet without or with eRapa at 14 mg/kg food, which results in an approximate dose of 2.24 mg/kg body weight per day, and yielded rapamycin blood levels of about 4 ng/ml. Surprisingly, we found that eRapa dramatically extended life span of both female and male Rb1+/- mice, and slowed the appearance and growth of pituitary and decreased the incidence of thyroid tumors commonly observed in these mice. In this model, eRapa appears to act differently than DR, suggesting diverse mechanisms of action on survival and anti-tumor effects. In particular the beneficial effects of rapamycin did not depend on the dose of Rb1.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.18632/aging.100533
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Livi, C.B., Hardman, R.L., Christy, B.A., Dodds, S.G., Jones, D., Williams, C.E., Strong, R., Bokov, A.F., Javors, M.A., Ikeno, Y., Hubbard, G.B., Hasty, P., &amp; Sharp, Z.D. (2013). Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. <em>Aging</em>. https://doi.org/10.18632/aging.100533
Vancouver
Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams CE, et al. Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors. Aging. 2013. doi:10.18632/aging.100533.
BibTeX
@article{carolina2013Rapamy, title = {Rapamycin extends life span of Rb1+/− mice by inhibiting neuroendocrine tumors}, author = {Carolina Becker Livi and Rulon L. Hardman and Barbara A. Christy and Sherry G. Dodds and Diane Jones and Charnae E. Williams and Randy Strong and Alex F. Bokov and Martin A. Javors and Yuji Ikeno and Gene B. Hubbard and Paul Hasty and Zelton Dave Sharp}, journal = {Aging}, year = {2013}, doi = {10.18632/aging.100533}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings